A phase IV, open-label study of the adhesion and dermal tolerability of EMSAM (selegiline transdermal system) in healthy adults subjects of two age groups (18-64 years, and 65 years and older)

Trial Profile

A phase IV, open-label study of the adhesion and dermal tolerability of EMSAM (selegiline transdermal system) in healthy adults subjects of two age groups (18-64 years, and 65 years and older)

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jan 2010

At a glance

  • Drugs Selegiline (Primary)
  • Indications Alzheimer's disease; Depressive disorders; Parkinson's disease
  • Focus Pharmacodynamics
  • Sponsors Somerset Pharmaceuticals
  • Most Recent Events

    • 04 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top